Skip to main content

Therapy of traumatic brain injury by modern agents and traditional Chinese medicine


Traumatic brain injury (TBI) is the leading cause of disability and death, and the social burden of mortality and morbidity caused by TBI is significant. Under the influence of comprehensive factors, such as social environment, lifestyle, and employment type, the incidence of TBI continues to increase annually. Current pharmacotherapy of TBI mainly focuses on symptomatic supportive treatment, aiming to reduce intracranial pressure, ease pain, alleviate irritability, and fight infection. In this study, we summarized numerous studies covering the use of neuroprotective agents in different animal models and clinical trials after TBI. However, we found that no drug has been approved as specifically effective for the treatment of TBI. Effective therapeutic strategies for TBI remain an urgent need, and attention is turning toward traditional Chinese medicine. We analyzed the reasons why existing high-profile drugs had failed to show clinical benefits and offered our views on the research of traditional herbal medicine for treating TBI.


Traumatic brain injury (TBI) leads to extensive neurologic disability and mortality rates worldwide [1]. Diagnoses range from mild TBI to moderate and severe TBI depending on the severity of the injury. The incidence of TBI has increased during the last few decades, with an important impact on public health. It has been estimated that more than 60 million people worldwide remain injured after experiencing TBIs of varying severities [2]. Falls as well as motor vehicle and work-related accidents are the most frequent causes of TBI [3, 4]. Despite the progress that has been made in diagnosis, neurosurgical care, and functional rehabilitation, no effective therapy is currently available for TBI.

Multiple drugs have been studied to treat TBI in animal models and patients. Among them, hyperosmotic drugs were used for reducing intracranial pressure; anticoagulant drugs were used to treat deep venous thrombosis in the brain; antiepileptic drugs were used for preventing or controlling epilepsy; and antibiotics were applied to prevent or control infection (Fig. 1). Currently, many new drugs are being examined in clinical trials [5]; meanwhile, many types of existing drugs that have been used to treat other diseases are being trialed for TBI [6], with some even having entered phase III clinical trials (Table 1). In addition, an increasing number of researchers have tested herbal medicines and achieved good results [7]. This review sought to summarize and assess the effectiveness of these drugs for TBI (Tables 2, 3, 4, 5) and offered some expectations of research in the future.

Fig. 1
figure 1

Multipotential drug treatment strategies for TBI

Table 1 Clinical trials in patients with TBI per trial phase
Table 2 Treatment with modern drugs of entering clinical trials in animal models post-TBI
Table 3 The neuroprotective effects of herbal medicines on animal models post-TBI
Table 4 The neuroprotective effects compounds of Traditional Chinese medicines on animal models post-TBI
Table 5 The neuroprotective effects of Formulae and Decoctions of Traditional medicines on animal models post-TBI

Modern agents

Inclusion criteria

PubMed [National Library of Medicine/National Institutes of Health (NLM/NIH)], Web of Science [Institute of Scientific Information, ISI], and [National Library of Medicine/National Institutes of Health (NLM/NIH)] were searched for privately and publicly funded clinical studies conducted around the world. All studies were conducted before 23 January, 2023. The databases were searched using both controlled vocabulary words and synonymous free-text words for the topic of interest (TBI, agent, drug, medicine, and medication). This review included clinical trials, randomized controlled trials (RCTs), controlled clinical trials, and observational studies; both sexes (female and male); all age stages [child (birth–17 years), adult (17–65 years), and older adult (65 years)]; and all study phases. Approximately 120 drugs have been or will be investigated in 512 clinical trials. We focused on therapies approved by the United States Food and Drug Administration (FDA) or European Medicine Agency (EMA), which were widely applied in indications for other diseases, as they should have a decent chance of succeeding. Considering their well-known side effects, it is easier to assess the benefit/risk stability of these drugs. Therefore, we restricted “modern agents” to the following potential strategies that have been extensively examined in animal models of TBI: corticosteroids, progesterone, β-blockers, citicoline, statins, tranexamic acid, erythropoietin (EPO), amantadine, caffeine.


Corticosteroids have been widely used to treat inflammatory-mediated and immune-related diseases because of their anti-inflammatory and immunosuppressive effects. It is well known that secondary brain edema and swelling increase intracranial pressure, leading to further distortion of the structure of the brain as well as reduced cerebral blood perfusion and oxygen content. To date, corticosteroids have been used to treat TBI for more than 40 years. Previous animal studies of TBI have shown that treatment with corticosteroids exerts neuroprotective effects by reducing the expression of CD31+ cells and circulating endothelial progenitor cells (EPCs) [8], glucocorticoid receptor (GR) [9], TGF-β1, IL-1β, TNF-α [10], and activated microglia/infiltrated macrophages [11], as well as by increasing the expression of mineralocorticoid receptor (MR) and IL-10.

A large-scale multicenter double-blinded International Standard Randomized Controlled Trial (ISRCTN74459797), Corticosteroid Randomization After Significant Head Injury (CRASH), randomized 10,008 patients with TBI to a 48-h infusion of 0.4 mg corticosteroid versus placebo [12] and explored the risk of death and disability after TBI. The investigators restricted study participation to patients who were at least 16 years old and had a Glasgow Coma Scale (GCS) score of no more than 14 points in the hospital, while those with contraindications to glucocorticoids were excluded from the study. The primary end point was the rate of deaths within 14 days after injury or the presence of disability up to 6 months later. The results indicated that corticosteroid treatment significantly increased the 2-week mortality rate compared with placebo (17.9% vs. 21.1%; P < 0.001), but there was no difference between the two treatment arms regarding disability at 6 months. Moreover, there was no difference in the composite outcome of certain complications, such as hypertension and immunosuppression. Based on this study, corticosteroids are not recommended for routine use in the treatment of TBI.


Progesterone is a female steroid hormone that easily crosses the blood–brain barrier and is well tolerated. Notably, progesterone has potent neuroactive and neurosteroid effects in the treatment of brain injury. Many preclinical studies have reported that progesterone improves motor and cognitive function by reducing the levels of excitatory postsynaptic currents (EPSCs), inhibitory postsynaptic currents (IPSCs), intracranial pressure (ICP), Bcl-2, and IL-6, as well as by increasing the expression of excitatory amino acid transporter 3 (EAAT-3), β subunit of the voltage-gated sodium channel NaVβ3, suppressor of cytokine signaling-3 (SOCS-3), phosphorylated signal transducer and activator of transcription-3 (p-STAT-3), NF-κB-P52, p-NF-κB-P65, and nerve growth factor (NGF) in experimental TBI models [13,14,15,16,17]. Meanwhile, in two large double-blinded phase III RCTs (ProTECT III and SyNAPSe), more than 2,000 patients were investigated. Those studies failed to demonstrate a clinical benefit in terms of postoperative mortality and functional outcomes after TBI [18, 19], even resulting in the termination of subsequent clinical trials investigating progesterone.


β-Blockers, a class of cardio-cerebrovascular–protective drugs, play a major role in preventing the release of excitatory neurotransmitters, thereby promoting nerve injury repair in TBI. In recent years, a growing amount of experimental evidence collected from animal studies has suggested that β-blockers have neuroprotective effects against TBI via a mechanism that involves the reduction of leukocyte rolling and p-tau [20, 21].

Schroeppel et al. [22] reported that propranolol had a protective effect on TBI and reduced the mortality rate in a prospective randomized pilot trial, despite their failure to show differences between the exposed and nonexposed arms. Similar results were found in a prospective RCT [6], where 119 patients (age ≥ 18 years) were randomly divided into a group that was given 20 mg propranolol orally every 12 h for up to 10 days or until discharge from the hospital and a group that did not receive propranolol. No significant difference in the in-hospital mortality rate was recorded between patients exposed to β-blockers and those not exposed. In contrast, patients who received propranolol experienced dramatically decreased mortality compared with those in the unexposed arm after applying specified exclusion criteria, which satisfied the conditions that “severe TBI = intracranial abbreviated injury scale (AIS) ≥ 3, with all extracranial injuries ≤ 2.” Despite its prospective randomized design, the current 14 trials were limited by many confounding factors. First, some trials lacked blinding or placebo and were limited by the involvement of one trauma center only. Second, more homogeneous research population and multicenter studies were lacking. Mortality rates among TBI patients with different conditions were not comparable. Finally, the control of single-dose β-blockers was not suitable during hospitalization, causing some patients not to receive the same number of single-dose β-blockers during the trial.


Citicoline is an activator of brain metabolism that can develop into cytidine (or uridine in humans) and choline through hydrolysis and dephosphorylation. Subsequently, citicoline is resynthesized by hydrolysis and dephosphorylation as the material base of cytidine and choline after passing the blood–brain barrier. As a result, it plays an intracellular neuroprotective role by supporting the biosynthesis of phospholipids. Therefore, citicoline is considered a potential drug for the treatment of partial secondary brain injury. Currently, many preclinical studies have focused on the neuroprotective effects of cytidine on TBI. The mechanisms involve anti-inflammation by the reduction of S-100β, IL-6, and neuron-specific enolase (NSE) [23,24,25]; However, the neuroprotective effect of citicoline remains unproven in clinical trials.

The only citicoline clinical phase III trial in TBI, a double-blinded randomized trial known as Citicoline Brain Injury Treatment (COBRIT) trial that was performed in the United States from July 20, 2007, to February 4, 2011, investigated whether citicoline administered within 24 h could improve functional and cognitive status in humans with mild, moderate, or severe TBI. A total of 607 patients were randomized to receive citicoline at a dose of 1,000 mg twice daily for 90 days by an oral or enteral administration route, and 606 patients were administered a placebo. This study revealed that acute and subacute treatment with citicoline failed to yield evidence of amelioration in brain function and cognition relative to placebo. However, a subsequent secondary analysis using recovery curves with repeated measures showed that most patients had favorable outcomes at 180 days after injury in all TBI groups. There was substantial amelioration in all of the groups from 1 to 180 days after injury, and this improvement can last beyond 180 days [26].

More studies have adopted similar approaches and applied multimodal and longitudinal datasets to analyze their results [27]. However, additional studies are needed to prove the therapeutic effect of citicoline, and currently, there is insufficient evidence available to support the recommendation of citicoline in patients with TBI.


Statins, also known as 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, are a kind of medication generally prescribed to treat elevated cholesterol levels. Statins work to competitively inhibit HMG-CoA reductase by blocking the intracellular hydroxyvalerate metabolism pathway and reducing endogenous cholesterol synthesis, which leads to reflexive stimulation of the quantity and activity of low-density lipoprotein receptors on the surfaces of cell membranes, thereby reducing the level of cholesterol in serum [28]. Previous studies [28,29,30] have confirmed the beneficial effects of these drugs not only in hyperlipidemia but also in TBI. Moreover, previous animal studies [28, 29] of TBI have shown that treatment with statins exerts neuroprotective effects by increasing the expression of endothelial nitric oxide synthase (NOS), promoting neurogenesis and synaptogenesis, increasing angiogenesis, and enhancing antioxidant and anti-inflammatory properties. Possible mechanisms are associated with anti-inflammation and anti-apoptosis effects of nerve cells by the reduction of microglia activation, TNF-α, IL-1β, NF-κB, CD40, TANK binding kinase 1 (TBK1), Toll-like receptor 4 (TLR4), glucose-regulated protein 78 (GRP78), and Nrf2 [28,29,30,31,32]. However, few studies have focused on the effects of statins on the functional prognosis of humans with TBI.

A retrospective study investigated differences in in-hospital mortality rates between prior statin users and nonusers among TBI patients. A total of 116,193 patients were included in this study, and the statins in question included atorvastatin, lovastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin. The authors concluded that statins can significantly reduce in-hospital mortality after TBI [30]. Moreover, pre-TBI statin use could be related to a survival benefit and improvements in neurologic function in TBI patients [33]. However, it should be noted that these findings were gathered from a single-center observational study of the older patient population. Furthermore, a phase II clinical trial explored whether the administration of atorvastatin for 7 days after injury was safe in 140 patients with mild TBI randomized to receive either atorvastatin (1 mg/kg per day for 7 days) or placebo within 24 h of injury. No serious adverse effects associated with atorvastatin treatment occurred, and the authors concluded that the administration of atorvastatin for 7 days after TBI was safe but not effective in the improvement of functional outcomes, such as neurologic recovery [34]. Similar conclusions have been reached in the recent studies conducted by Soltani et al. [35] and Mansi et al. [36]. Although their results seemed to suggest some progress, they were limited by using a retrospective study design, small sample size, or single severity degree of TBI, and larger prospective RCTs are required to evaluate the potential effects and clinical benefits of statins after TBI.

Tranexamic acid

Tranexamic acid (TXA) is a derivative of lysine. It is known as an anti-fibrinolytic drug, which does not increase the synthesis of fibrin in the process of hemostasis. It exerts hemostatic effects by reversing binding to the lysine site to block binding on plasminogen, thereby reducing the level of fibrinolysis [37]. Hemorrhage and edema are associated with poor clinical outcomes in TBI. From a theoretical view, TXA can achieve hemostasis without increasing the risk of thromboembolic events [38] and is a potential agent for the treatment of TBI.

In the past decade, the potential effects of TXA in animal models of TBI have been confirmed. Studies of TBI have shown that treatment with TXA exerts neuroprotective effects of immunoregulation and anti-inflammation by increasing the levels of macrophage inflammatory protein 1α (MIP-1α), lymphoid cell populations, monocyte subsets, and dendritic cells, and reducing the levels of monocyte chemoattractant protein-1 (MCP-1), IL-6, IL-1β, TNF-α, p-tau, and NSE [39,40,41,42]. Clinical trials have also drawn increasing attention. We summarize three randomized, placebo-controlled trials in which the potential brain-protective effects of TXA therapy after TBI were investigated in the setting of bleeding trauma. In one case–control study (NCT00375258), Clinical Randomization of an Anti-fibrinolytic in Significant Hemorrhage 2 (CRASH-2), the effects of TXA therapy on death, vascular occlusive events, and blood transfusion in 20,211 patients with bleeding trauma were investigated at 274 hospitals in 40 countries. The results suggested that TXA dramatically reduced mortality in terms of the absence of increased vascular occlusive events but failed to confirm less mortality in a TBI subgroup [43]. Moreover, researchers further evaluated the effects of TXA in patients with TBI in CRASH-3 (NCT01402882), where 12,737 patients with TBI were randomly allocated to a TXA group, where they received a 1-g loading dose over 10 min, followed by an infusion of 1 g over 8 h, or a matching placebo group. This study offered evidence that TXA is safe in patients with TBI and can reduce TBI-related deaths. Importantly, the optimal time window of treatment is within 3 h of injury [44].

However, CRASH-3 only included patients with mild TBI who showed intracranial hemorrhage on computed tomography scans, and it remains to be determined whether its results could be applied to patients with mild TBI more generally. Thus, the foundation for CRASH-4 (NCT04521881)—which plans to seek reliable evidence of the effects of early intramuscular TXA on disability, death, and dementia in older patients with intracranial hemorrhage with symptomatic mild TBI—has been laid. Furthermore, another forthcoming study (NCT04387305) designed to assess the benefits and harms of TXA in severely traumatic children with hemorrhagic brain injuries and/or injury to other parts, such as the trunk, is eagerly anticipated.

Erythropoietin (EPO)

EPO is a glycoprotein produced by the kidneys that regulates bone marrow hematopoiesis, resulting in the natural production of erythrocytes following hypoxic stimulation. EPO production occurs not only in the bone marrow, liver, spleen, and lungs but also in the brain. Currently, the two main indications for EPO agents approved by the FDA are anemia secondary to chronic kidney disease in patients with nephrosis and chemotherapy in cancer patients [45]. Preclinical studies have shown that EPO acts as a neurotrophic factor, which can relieve the impact of secondary brain damage by the blockade of the apoptotic program, improvement of neurogenesis, and inhibition of an inflammatory response. The specific mechanisms are associated with the reduction of NF-κB, NSE, GR, GFAP, and S100 and the elevation of GPX, SOD, GSH/GSSG, HIF-1α, mitogen-activated protein kinase (MAPK), cyclic adenosine monophosphate (cAMP), and aquaporin 4 (AQP4) [46,47,48,49]. However, it remains controversial whether EPO has neuroprotective effects in TBI.

In a double-blinded RCT with 159 patients, the short-term efficacy of early treatment with recombinant human EPO after severe TBI was investigated. Treatment was initiated within the first day in patients with a GCS score of 8 points or less upon arrival, who received EPO (100 units/kg) or placebo on days 1, 3, 6, 9, and 12 after injury. It was demonstrated that patients in the EPO treatment group had lower GCS scores and lower levels of NSE and S-100β protein in serum than the placebo group following the first 3 months after administration. The authors concluded that recombinant human EPO can improve three-month functional recovery in patients with severe TBI and that it does not increase the incidence of thromboembolic events or severe infection [50]. However, in a large multicenter, double-blinded, parallel-group RCT (NCT00987454) with 606 patients with moderate to severe TBI, Skrifvars et al. [51] evaluated the efficacy of EPO treatment (40,000 IU subcutaneously per week) versus placebo (0.9% physiological saline) and found that EPO administration did not improve severe neurologic dysfunction or reduce 6-month mortality. Similar findings were confirmed in other studies, without an increased risk of deep vein thrombosis events or severe infections [50, 52, 53]. However, these studies had several limitations, including the small sample size and the absence of long-term outcome follow-up data. Therefore, a new study, Erythropoietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill Trauma Patients (NCT04588311), is currently recruiting participants.


Amantadine is an indirectly acting dopamine agonist with presynaptic and postsynaptic effects. In addition, it is a noncompetitive N-methyl-d-aspartate antagonist. The neuroprotective effect of amantadine in experimental TBI has been confirmed. Previous studies have found that the administration of amantadine could improve neural regeneration in rats with TBI by reducing the expression of degenerating neurons and DNA fragmentation [54, 55].

In a small, double-blinded, single-center, phase II RCT study, 42 patients with severe TBI were randomized to receive either amantadine or a placebo for 6 weeks. GCS and FOUR scores were recorded on days 1, 3, and 7 following treatment with placebo or amantadine, and Mini-Mental State Examination, Glasgow Outcome Study, Disability Rating Scale scoring, and Karnofsky Performance Scale scoring were conducted after the drug was administered. The authors concluded that there was essentially no effect on the behaviors, consciousness, cognitive function, and mortality of patients with severe TBI at 6 months [56]. Another multicenter, parallel-group, double-blinded RCT investigated the effects of amantadine on cognition in 119 patients with chronic TBI (lasting 6 months or more postinjury) and did not find significant effects of amantadine treatment, even showing that cognitive processing may be hampered during the first 28 days of administration of amantadine [57].

However, a recent triple-blinded, placebo-controlled randomized study evaluating the effects of amantadine on brain dysfunction in 57 patients demonstrated that amantadine can hasten the recovery of functional ability in patients with severe TBI [58]. Unfortunately, the study did not have a large sample size and offered long-term data only for a single population (i.e., for patients from the Imam Reza Hospital neurosurgery ward). Some researchers have found that the combination of amantadine and other drugs, such as citicoline, Cerebrolysin, and memantine, may improve prolonged disorders of consciousness in patients with TBI [59, 60].

Two relevant phase IV clinical studies, Combination Treatment with Cerebrolysin and Amantadine on Patients Who Stay in Prolonged Disorders of Consciousness Due to Severe Traumatic Brain Injury and the Citicholine–Amantadine Trial in Traumatic Brain Injury (NCT04427241), are currently in progress.


Caffeine is one of the most widely consumed addictive compounds by a huge population worldwide and has multiple effects on the central nervous system. It is well known that extreme doses of caffeine can cause neurotoxicity [61]. Notably, common-dose of caffeine can be a double-edged sword in TBI models of different genders and/or therapeutic windows.

Lusardi et al. [62] demonstrated that instead of caffeine withdrawal, chronic caffeine therapies (0.3 g/L caffeine exposure for 3 weeks pre-TBI; 0.3 g/L caffeine exposure for 1 week post-TBI) impeded the improvement of motor function. More importantly, despite chronic caffeine preexposure, a single acute dose of caffeine (25 mg/kg) after TBI can prevent lethal apnea and has no negative impacts on motor function after sublethal injuries. A subsequent study showed that a common dosage of caffeine (1 g/L, approximately equivalent to five cups of coffee per day) caused the greatest detriments to both behavioral and cognitive functions in males, while the most considerable impairments in females were related to tasks associated with pain. Caffeine elevated spine density in the orbitofrontal cortex (OFC), medial prefrontal cortex (mPFC), and nucleus accumbens (NAc), which was thought to be due to damage in the routine pruning processes following TBI [63]. In a rather unusual study, before mating with control females, sires were kept in conventional cages or cages with running wheels and were given standard drinking water, caffeine, or ethanol for 7 weeks. At postnatal day 40, infants received TBI or sham injuries, and their postconcussive symptoms were evaluated. This study showed that offspring of caffeine-treated sires had higher levels of dopamine receptor D1 (Drd1), dopamine receptor D2 (Drd2) Drd2, GFAP, and DNA methyltransferase 3A (Dnmt3a) expression, as well as longer telomeres, which offered additional proofs that paternal caffeine exposure before conception affects the development of the offspring [64]. More preclinical and clinical research should be done in the future because existing studies on caffeine's effects in the treatment of TBI have shown results that appear to be contradictory.

Traditional herbal medicine

Modern medicine is largely dominated by phases I, II, III, and even IV clinical trials (Table 1); meanwhile, herbal medicines are widely used all over the world. Herbal medicines have been tested on humans for thousands of years instead of being tested on animals, and concrete effects have been recorded. Among all of the drugs approved by the FDA, 25% are derived from traditional herbal medicines [7]. We highlight the potential neuroprotective value of traditional Chinese herbal medicine in TBI, including combination formulas, single herbs, and active compounds, as well as their mechanisms of action.

Single herbs and their active compounds

Panax ginseng (P. ginseng), also known as ren shen, is native to China and Korea and is sourced as the dried root of a plant in the Araliaceae family [65]. The actions of P. ginseng were investigated post-TBI in a controlled cortical impact (CCI) mouse model, and the possible mechanisms were related to the MAPK/NF-κB signaling pathway [66] and HO-1-mediated AMPKα-PGC-1α-ERRα circuit after TBI [65]. P. ginseng contains many active compounds, such as Rg1, Rb1, and Rb2. Treatment with ginsenoside Rg1 in a weight drop injury (WDI)-induced TBI rat model ameliorated cerebrovascular cellular damage by elevating the expression levels of TIMP3, VEGF, GFAP p-P65/P65, ZO-1, occluding, and claudin-5, and by hampering the levels of exos-miR-21 and MMP1/3/9 [67]. Zou et al. [68] found that ginsenoside Rb1 treatment exerted a neuroprotective effect in rats with TBI via reversing the fluid percussion injury (FPI)-induced downregulation of connexin40, and enhancing the expression levels of p-ERK1/2.

Carthamus tinctorius L. is a dried flower of the composite family that has been used in traditional herbal medicine to treat various conditions, including thrombosis, menstrual flow irregularities, spasms, and flatulence. C. tinctorius L. contains many active compounds, such as crocin, crocetin, safranal, and isophorone, although so far researchers have only found that crocin has a neuroprotective role in TBI. Treatment with crocin in a CCI-induced TBI mouse model enhanced the anti-inflammatory and antioxidant effects by increasing the expression levels of NSS and GSH and by reducing the expression levels of IFN-γ, TNF-α, MPO and MDA [69].

Panax notoginseng, also known as sanqi, belongs to the Araliaceae family. P. notoginseng is known as “the miraculous agent capable of stopping the blood” and is commonly used for promoting blood circulation, relieving blood stasis, and alleviating pain in China. P. notoginseng contains many active compounds, such as P. notoginseng saponins (PNS), dencichine, flavones, and ginsenoside [70]. Thus far, researchers have found that ginsenoside has a neuroprotective role in TBI. Jiang et al. [71] found that the administration of P. notoginseng had neuroprotective effects against TBI by reducing the level of p-p65, thromboplastin time (t-PA), prothrombin time (PT), activated partial thromboplastin time (APTT), and endothelin (ET), and by elevating the levels of CD61 and CD62. Furthermore, an injection of PNS intraperitoneally after the induction of TBI in a WDI rat model improved behavioral test results via increasing the expression of phosphatidylinositol 3-kinase (P13K), Akt, and mTOR [72].

Gastrodia elata belongs to the Orchidaceae family. Its dried rhizome is commonly used for the treatment of neurologic disorders, such as headache, stroke, Alzheimer's disease, and vertigo [73]. In a rat model of TBI, the administration of G. elata aqueous extract showed neuroprotective effects against TBI. It also improved the rotarod test results and reduced the number of astrocytes, TNF, and IL-6 [74]. G. elata contains many active compounds, such as gastrodin, 4-hydroxybenzaldehyde, and vanillin; among them, gastrodin has been confirmed to have neuroprotective effects against TBI. The administration of gastrodin after the induction of TBI by CCI in a rat model remarkably suppressed pyroptosis and affected the anti-inflammatory action of nerve cells of rats by inhibiting the expression of Gasdermin D (GSDMD), NLRP3, ASC, caspase-1, and caspase-11 and by reducing proinflammatory cytokines such as TNF-α, IL-1β, and IL-18 [75]. Of note, in China, gastrodin tablets, a nonprescription drug extracted from G. elata, have been approved for use in neurasthenia, headache, and migraine by the State Drug Administration [76].

Rheum palmatum is sourced as the dried root of a plant in the Polygonaceae family. The effect of R. palmatum after TBI was investigated in a rat model created by CCI. It was shown that its aqueous extract was able to relieve edema by impeding the extracellular signal–regulated kinase signaling pathway, reducing the levels of matrix metalloproteinase 9 (MMP-9), ROS, and p-ERK, and increasing the level of ZO-1 [77]. Moreover, anthraquinone glycosides from Rhubarb can play a protective role in rats with cerebral injury by increasing the levels of 5-hydroxytryptamine (5-HT), 5-hydroxy indole acetic acid (5-HIAA), and γ-aminobutyric acid (GABA), and contents of glutamic acid (Glu) and aspartic acid (Asp) [78]. Rhein and Emodin are isolated from R. palmatum and have neural benefits in TBI. Rhein can be absorbed by brain tissues following oral administration in TBI rats, which prevents neurologic impairment in mice following TBI by inhibiting neuronal pyroptosis. Moreover, Rhein remarkably decreases the levels of lactate dehydrogenase (LDH), GSDMD, NOD-like receptor protein 3 (NLRP3), TLR4, MyD88, NLRP3, IL-1β, IL-18, and IFN-γ, and increases the content of p10, p20, and p45 [79]. In vivo, emodin can exert neuroprotective effects by elevating NF-κB p65, intercellular cell adhesion molecule-1 (ICAM-1), S100B, IL-6, and TNF-α, and by suppressing NF-κB p65, ICAM-1, S100B, IL-6, and TNF-α [80].

Ginkgo biloba is collected in the form of a dried leaf from a plant of the Ginkgoaceae family. The effect of G. biloba extract was evaluated in a post-TBI rat model caused by CCI. The oral administration of G. biloba extract after injury in rats remarkably improved NSS and reduced brain edema. G. biloba also diminished the expression levels of VEGF, phosphatidylinositol3-kinase (PI3K), p-AKT, and MMP-9 to reduce oxidative stress and inflammation [81]. Ginkgolide B is isolated from G. biloba and has a neural benefit in TBI. The oral administration of ginkgolide B following the induction of TBI by WDI in a rat model remarkably reduces the number of apoptotic nerve cells by a reduction in Omi/Htr A2, procaspase-3, procaspase-9, and cleaved poly ADP-ribose polymerase, and the elevation of X-linked inhibitor of apoptosis protein [82].

Polygonum cuspidatum refers to the dried root and stem of a plant from the Polygonaceae family. As one of the famous traditional Chinese medicines (TCMs), P. cuspidatum is usually used in the treatment of jaundice, hyperlipidemia, infections, and inflammatory conditions [83]. The neuroprotective effects of resveratrol are associated with SIRT1/PGC-1 signaling in mice with TBI. The administration of resveratrol after TBI significantly reduces the expression of P-p38 MAPK 86; increases the expression of SIRT1/PGC-1 signaling, including SIRT1, PGC-1, and synaptophysin (SYN); relieves edema; and increases the ability to fight cognitive impairment [84]. Moreover, resveratrol remarkably improves cognitive function and reduces cerebral inflammation and edema by elevating the levels of P62, P-pI3K, P-Akt, and P-mTOR, and by reducing the levels of LC3 II, Beclin-1, IL-1β, and TNF-α [85].

Curcuma longa refers to the dried rhizome of a plant from the Zingiberaceae family. It has been used to treat several conditions, such as inflammation, tumor, asthma, and immune dysfunction [86,87,88]. The neuroprotective effects of curcumin are associated with p38/MAPK signaling in mice with TBI. The oral administration of curcumin after TBI significantly reduces the expression of p38/MAPK signaling, including p-p38 and NF-κB; decreases the expression of IL-1β, IL-6, and TNF-α; and increases the ability to fight against neurologic impairment [89]. Additionally, the administration of curcumin after TBI reduces spatial memory decline; increases neurogenesis; and upregulates the expression of BNDF, tyrosine kinase receptor b (Trkb), PI3K, and AKT [90].

Salvia miltiorrhiza refers to the dried root and rhizome of a plant from the Lamiaceae family. Salvianolic acid A is extracted from Salvia miltiorrhiza, China, S. miltiorrhiza injection, which is a standardized agent, has widely been used in clinical treatment [91,92,93]. and the administration of salvianolic acid A intraperitoneally after TBI significantly diminishes brain water content, ameliorates NSS and spatial learning and memory functioning, and reduces the levels of TNF and IL-1β, thereby exerting neuroprotective effects [94]. Tanshinone IIA is also derived from Salvia miltiorrhiza, which can significantly inhibit oxidative stress and apoptosis by the reduction of p47phox, CD11, AQP4, glial fibrillary acidic protein (GFAP), malondialdehyde (MDA), catalase (CAT), IL-1β, and TNF-α, and the elevation of SOD and GSH-PX [95].

Artemisia annua belongs to the Asteraceae family of plants. Until now, active compounds of A. annua have been evaluated in TBI models. The major active compounds of A. annua include flavonoids, phenolics, artemisinin, coumarins, sesquiterpenoids, and triterpenoids. Gugliandolo et al. found that artesunate was able to promote neuronal survival after TBI through the reduction of Nf-kb, inflammation body complex, GFAP, and Iba-1, and the elevation of BDNF, GDNF, and NT-3 [96]. In addition, the neuroprotective effects of artesunate in a CCI rat model showed that artesunate ameliorated the permeability of the blood–brain barrier and reduced brain water content and neuro-inflammation [97].

Formulae and decoctions

Taohong-siwu decoction (THSWD), an ancient TCM herbal formula consisting of six herbs (Carthami flos [Honghua], Semen persicae [Taoren], Angelicae sinensis radix [Danggui], Chuanxiong rhizoma [Chuanxiong], Rehmanniae radix praeparata [Shudihuang], and Paeoniae radix alba [Baishao]) in a 1:1:1:1:1:1 mass ratio, was first described in Wu Qian’s Yi Zong Jin Jian during the Qing dynasty. In TCM practice, it is believed that THSWD can mitigate blood stasis in case the blood becomes too sticky and generates blood clots. THSWD is not only capable of mitigating cardiovascular disease but is also effective in alleviating TBI-induced headache, dizziness, memory deterioration, and mean peak velocity of cerebral blood flow [101]. Wang et al. found that THSWD has a valid effect on TBI-induced neurologic disorder by the activation of the Wnt/β-catenin signal pathway and the elevation of BDNF and NGF levels [102].

Xuefu Zhuyu decoction (XFZYD), an ancient classical herbal formula first reported in Yi Lin Gai Cuo by the distinguished medical scientist Wang Qingren during the Qing dynasty, is mainly composed of 11 herbs (Semen persicae [Taoren], Carthami flos [Honghua], Angelicae sinensis radix [Danggui], Rehmanniae radix praeparata [Shudihuang], Achyranthes bidentata [Niuxi], Paeonia lactiflora [Chishao], Citrus aurantium [Zhiqiao], Glycyrrhiza uralensis [Gancao], Chuanxiong rhizoma [Chuanxiong], Platycodon grandiflorum [Jiegeng], and Bupleurum chinense [Chaihu]) in a 4:3:3:3:3:2:2:1.5:1.5:1 mass ratio. In TCM practice, it is generally believed that XFZYD can activate blood circulation and resolve stasis during the treatment of cardiovascular disease [103]. The neuroprotective effects of XFZYD in a CCI rat model demonstrated that XFZYD mitigated cognitive disorder; improved spatial learning and memory functions; and reduced the expression of Ppfia3, Rab11a, Rnf216, and Rnf6 messenger RNA after TBI [104]. Moreover, XFZYD improved neurologic function without destroying coagulation function [105].

Buyang huanwu decoction (BYHWD), a classical formula, also prescribed by Wang Qingren in Yi Lin Gai Cuo, consists of seven herbs, namely Astragalus (Huangqi), Angelicae sinensis radix (Danggui), Paeonia lactiflora (Chishao), Semen persicae (Taoren), Carthami flos (Honghua), Chuanxiong rhizoma (Chuanxiong), and Pheretima aspergillum (Dilong) in the mass ratio of 40:2:2:1:1:1:1. BYHWD is commonly used to treat cerebrovascular diseases in the sequela stage because of qi insufficiency and blood stasis [106]. Wang et al. [102, 107] found that treatment with BYHWD after TBI in rats improved the pathological damage in brain tissue and decreased the levels of GFAP and Tau in serum. In addition, BYHWD was shown to be able to alleviate neurologic disorders after injury by activating the Wnt/β-catenin signaling pathway and elevating the expression levels of BDNF and NGF. Of note, the effect of BYHWD against TBI was equivalent to that of Tongqiao-huoxue decoction (TQHXD).

Wuling san (WLS), a famous classical formula first mentioned in ShangHan Lun by the distinguished medical scientist Zhang Zhongjing during the Eastern Han dynasty, consists of five herbs, including Alisma orientale (Zexie), Atractylodes macrocephala (Baizhu), Polyporus umbellatus (Zhuling), Poria cocos (Fuling), and Cinnamomum cassia Presl (Guizhi) in the mass ratio of 4:3:3:3:2. The neurotherapeutic effect of WLS in mice with TBI correlates with diminished water content and the elevation of messenger RNA levels of PGC-1α and NRF1, thereby promoting mitochondrial biosynthesis and enhancing the supplementation of energy to the brain tissue [108]. In addition, modified WLS could exert neurotherapeutic effects by the reduction of inflammatory cytokine contents in serum, including IL-6, IL-8, and TNF, as well as by decreasing the brain water content after TBI [109].

Wendan decoction (WDD) is a famous traditional herb formula that typically contains Pinelliae rhizoma (banxia 6 g), Bambusae caulis (zhuru 6 g), Pericarpium citri reticulatae (chenpi 9 g), Fructus aurantii immaturus (zhike 6 g), Poria cocos (fuling 4.5 g), Zingiberis rhizoma (ganjiang 5 pieces), Jujube (dazao 1 piece), and Radix glycyrrhizae (gancao 3 g). It was first described in Prescriptions Worth Thousand Gold for Emergencies by the distinguished medical scientist Sun Simiao during the Tang dynasty, and it was often used in the treatment of cardiovascular disease, gastrointestinal upset, and mental disorders [110]. In an RCT of TBI, the administration of WDD could improve neurologic function following acute TBI without generating mortality in the WDD group [111]. However, additional animal experiments and clinical trials on the efficacy of WDD in the treatment of TBI are needed.

Dachengqi Decoction (DCQD) is a classical herb pairing composed of Rhubarb (dahuang), Fructus aurantii (zhike), Magnolia officinalis (houpo), and Mirabilite (mangxiao) in the mass ratio of 4:2:3:3. It has been commonly used in the treatment of brain diseases, such as TBI and headache, due to wind pathogens and blood stasis. In mice with TBI, the administration of DCQD after TBI might successfully restore the intestinal mucosal barrier and enhance gastrointestinal motility by reducing the levels of diamine oxidase (DAO) and D-lactic acid [112].

Xiaochengqi Decoction (XCQD), a classical Chinese medicine, was first recorded from Shang Han Lun in approximately 200 AD and consists of Rhubarb (Dahuang), Fructus Aurantii Immaturus (Zhishi), and Cortex Magnoliae Officinalis (Houpo) in the mass ratio of 4:3:2. It is often used in the treatment of deficiency of qi and blood caused by the presence of long sores with heavy pus or blood loss. In a rat model of TBI, Peng et al. found that the administration of XCQD after injury had protective effects against brain water content and inflammatory response by reducing the levels of AQP4, and decreasing the levels of proinflammatory cytokines, including IL-1β and TNF-α [113]. The mechanism was confirmed in the subsequent study that demonstrated that XCQD had protective effects against TBI by reducing the number of harmful bacteria such as Bacteroidetes, Proteobacteria, Elusimicrobia, and Actinobacteria, and increasing the number of beneficial bacteria including Firmicutes and Spirochetes [114].

Tongqiao-huoxue decoction (TQHXD), a famous classical formula first recorded in Yi Lin Gai Cuo, consists of eight herbs (Moschus berezovskii [Shexiang], Carthami flos [Honghua], Zingiber officinale [Shengjiang], Semen persicae [Taoren], Paeonia lactiflora [Chishao], Ziziphus jujube [Dazao], Chuanxiong rhizoma [Chuanxiong], and scallion [Cong]) in a 0.15:9:9:6:6:6:6:3 mass ratio. Yi Lin Gai Cuo recorded that TQHXD can promote blood circulation and dredge the channels, especially in the treatment of blood stagnation of face and head as well as their meridians [115]. Meanwhile, Wu et al. [116] found that TQHXD had neuroprotective effects against brain injury by increase expression of CD34, p-focal adhesion kinase (FAK) and p-Paxillin proteins and elevate the angiogenesis via the VEGF pathway, which indicated the potential of TQHXD as a drug for the management of TBI. Therefore, the experimental application of TQHXD in the treatment of TBI needs to be further carried out.

Combination treatment of physical methods with drugs

Acupuncture, a relatively well-acknowledged traditional physical therapy of TCM, has been utilized in China to relieve pain and boost body energy. Electroacupuncture (EA), which originated from traditional acupuncture in the 1930s, has been proven to significantly enhance traditional acupuncture's therapeutic effects in a range of diseases. A growing number of studies have shown that EA can help improve neurologic function after TBI by stimulating specific acupuncture points [117]. The stimulation of LI4 and LI11 acupoints on days 1, 2, 3, 4, and 5 after TBI restores sensorimotor, motor, learning, and memory deficits; recovers the levels of HDAC1 and HDAC3; and inhibits BDNF-related Akt/GSK-3 signaling in the cortex of TBI mice [118]. Liu et al. [119] found that auricular electroacupuncture combined with body acupuncture(PC6, GV26 and SP6) could significantly inhibit severe TBI-induced disorders of consciousness. Moreover, In a multicenter, single-blinded study, 250 patients with severe TBI-induced acute gastrointestinal injury received EA intervention at Zhongwan, Tianshu, bilateral Zusanli, Shangjuxu, and Xiajuxu acupoints for 30 min twice daily for 7 days in addition to conventional treatment that included mannitol, epilepsy treatment, infection prevention, and nutritional support. Scorse of gastrointestinal failure (GIF), Sequential Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation (APACHE II), GCS, Multiple Organ Dysfunction Syndrome (MODS) scores, D-lactic acid (D-lac), lipopolysaccharide (LPS), DAO, and intra-abdominal pressure (IAP) were recorded. The authors concluded that in individuals with severe TBI exacerbated by acute gastrointestinal injury, early EA and conventional treatment could enhance clinical prognosis and gastrointestinal function [120].


TBI is an extremely complex disease associated with multiple interacting secondary injury processes. Many promising therapeutic candidate drugs have been identified using experimental models, but, until now, none have successfully shown clinical benefits, and no drug is currently approved by the FDA for the treatment of TBI.

In this study, we summarized chemical compounds, herbal medicines, and combination treatment of physical methods with drugs, which show neuroprotective effects and therapeutic action on TBI. Some of these drugs could enter the clinical trial stage, but most were forced to terminate or withdraw in phase III or even phase II (Table 1). An international trial published in the Lancet reported that corticosteroids caused a higher risk of death rate within 2 weeks in patients with significant TBI. Moreover, certain complications, such as hypertension and immunosuppression, were not well controlled after taking corticosteroids, which caused the trial to declare a failure in the treatment of TBI [12]. A study in the Frontiers in Neuroscience reported that a large double-blinded phase III RCT [18] that investigated progesterone failed to achieve a clinical benefit in terms of postoperative mortality and functional outcomes after TBI, leading to the termination of subsequent clinical trials. In addition, progesterone caused more frequent side effects such as phlebitis or thrombophlebitis. It has been found that no serious adverse effects occurred in a phase II clinical trial of atorvastatin in mild TBI patients [34], but the treatment was not effective in the amelioration of neurologic recovery, although it has been shown in experimental studies that statins may have neuroprotective effects [28, 29]. In addition, Giorgi et al. concluded that the administration of atorvastatin for 7 days after TBI was safe but not effective in the improvement of neurologic recovery, leading to the termination in the phase II stage with the limitations of small sample size and single severity degree of TBI [34]. Although these trials seemed to suggest some progress, they failed to enter clinical phase IV and be applied for the clinical treatment of TBI.

In a prospective randomized pilot trial, Schroeppel et al. [22] found that beta-adrenergic blockade by propranolol had a protective effect on TBI and reduced the mortality rate, but there was no evidence to confirm that propranolol can be applied to the secondary injury, including intracranial hemorrhage, electrolyte disturbance, and pulmonary edema. A study published in the Lancet reported that TXA can reduce TBI-related deaths in patients with mild TBI who had intracranial hemorrhage on computed tomography scans within 3 h [44]. However, the study only targeted intracranial hemorrhage but not other targets, such as intracranial infection, pneumonia, pulmonary edema, and electrolyte disturbance. Presumably, the complex pathological process of TBI is the reason why the trials reported in this review failed to enter clinical phase IV and be applied for clinical treatment. Therefore, “single-compound, single-disease” drugs fail to alleviate TBI [18, 19, 43, 53].

The safety of herbal medicines for TBI should be taken into consideration. Yang et al. [77] concluded that feeding with a dose of 12 g/kg crude Rhubarb for 24 h alleviated the neurologic dysfunction of TBI. Furthermore, Zhang et al. [121] found that crude Rhubarb intragastric administration in a dose of 76 g/kg for 14 days was toxic to the hepatic and renal function of normal male juvenile mice. It is interesting to note that Rhubarb 's nephrotoxicity is largely related to its chemical components. The primary chemical components of Rhubarb were in the following sequences in terms of nephrotoxicity: chrysophanol > aloe-emodin > physcion > rhein > emodin. The nephrotoxicity of steamed-processed Rhubarb was evidently lessened. Reductions in the amount of bound anthraquinones were related to this. It indicates that for the same herb, using different extraction methods, too long administration time, and excessive dose could cause drug toxicity. Therefore, there is an urgent need to harmonize the method of herbal extraction, proper duration, and dosage to control the safety of herbal medicine.

Moreover, the described animal studies of TBI are somewhat different from clinical studies (Table 1). In the majority of the reports in this review, the main research objects of animal studies were rodents, and there are huge differences between humans and rodents in terms of anatomical morphology and metabolic characteristics. Meanwhile, the causes of TBI mainly include road injuries and falls [1,2,3,4], while the animal models relied on CCI, FPI, and WDI, which are not consistent with clinical TBI [77, 81, 98]. Furthermore, the sample size of animal studies (15) [46, 49] is far lower than that of clinical studies (57) [58], and the latter are mostly confined to the male sex; therefore, the conclusions drawn from such studies are limited. At last, their observation time and therapeutic window vary, so they cannot specifically reflect the changes in the disease course in the actual clinical treatment process.

Herbal medicine has been used for thousands of years in the treatment of neurologic disorders by focusing on a “multiple compounds, yet single target and/or disease” approach [102,103,104,105,106,107,108,109,110,111,112,113,114,115,116]. However, modern herbal research on TBI still has limitations. The quality standards and herbal medicine need national uniformity. In the numerous studies mentioned in this review, the herbs-producing regions and their compounds were not described in the openly published papers [74, 77, 99, 100]. Even when a source was mentioned, the catalog number was not marked, which directly represents the formulation and grade of the herbal medicine [67, 70, 75]. The source and catalog number of XFZYD were not mentioned either [104, 105]. Yang et al. [77] specified that Rhubarb was from Gansu Province, China, while the catalog number was not provided. Therefore, there is a need to uniform the quality standards of herbal medicine.

The subjectivity of acupuncture and EA should be strongly taken into account. Traditional acupuncture has many restrictions due to its subjectivity; for instance, therapists performing acupuncture must assure that the patient has attained a special feeling known as “de qi,” which demonstrates its curative effect. However, the therapist must change the needle's angle and depth to obtain “de qi,” which is based on the individual's experiences and is subjective. Acupuncture's effectiveness can also be difficult to measure and duplicate. Huang et al. [118] and Wu et al. [119] confirmed acupuncture’s curative effect on TBI, but none of them provided the needle's angle and depth. EA, which is characterized by parameter objectification, has therefore drawn increasing attention. However, looking for the best parameter setting is complicated. The EA therapy depends on the settings being chosen and applied correctly. Hung et al. [118] and Xing et al. [120] did not provide parameter settings of the bio-signaling of bodily responses brought on by EA activation, which could objectively monitor some physiological or biochemical changes in response to EA stimulation and observe the degree of “de qi.” Therefore, it is necessary to establish a bio-signaling feedback monitoring system to monitor the body changes and observe the degree of “de qi.”


Despite these limitations, overall research is very promising and shows that herbal medicine may be potentially neuroprotective in TBI. However, it is important to provide an accurate and simple method for herbal quality control. Moreover, detailed, rigorous, and systematized preclinical evaluation should be established before successful clinical transformation of those treatment strategies. Due to the complexity of the chemical constituents of herbal medicine, it is difficult to separate them on column within a short time, so there is a challenging problem in the clinical use of on column chromatography herbal medicine injection because its constituent elements are complex. Though the use of traditional herbal medicines in the clinical setting has a long history, and their efficacy has been proven in clinical trials, it is necessary to provide an accurate and simple method for herbal quality control. Furthermore, in consideration of the therapeutic effects of EA and some drugs on TBI, the combination of acupuncture with drugs can be vigorously developed in the future.

Availability of data and materials

The authors declare that all data supporting the findings of this study are available within the article and its uploaded attach files.



Traumatic brain injury


Food and Drug Administration


European Medicine Agency


Endothelial progenitor cells


Glucocorticoid receptor


Mineralocorticoid receptor


Corticosteroid Randomization After Significant Head Injury


Glasgow coma scale


Excitatory postsynaptic currents


Inhibitory postsynaptic currents


Intracranial pressure


Excitatory amino acid transporter 3


Suppressor of cytokine signaling-3


Phosphorylated signal transducer and activator of transcription-3


Nerve growth factor


Neuron-specific enolase


Citicoline Brain Injury Treatment


3-Hydroxy-3-methyl glutaryl coenzyme A


Nitric oxide synthase


TANK binding kinase 1


Toll-like receptor 4


Glucose-regulated protein 78


Tranexamic acid


Macrophage inflammatory protein 1α


Monocyte chemoattractant protein-1


Clinical Randomization of an Anti-fibrinolytic in Significant Hemorrhage 2




Mitogen-activated protein kinase


Cyclic adenosine monophosphate


Aquaporin 4


Orbitofrontal cortex


Medial prefrontal cortex


Nucleus accumbens


Dopamine receptor D1


Dopamine receptor D2


DNA methyltransferase 3A


Controlled cortical impact


Weight drop injury


Fluid percussion injury

P. ginseng :

Panax ginseng

C. tinctorius L.:

Carthamus tinctorius L

P. notoginseng L.:

Panax notoginseng


P. notoginseng Saponins


Thromboplastin time


Prothrombin time


Activated partial thromboplastin time




Phosphatidylinositol 3-kinase


Matrix metalloproteinase 9




5-Hydroxy indole acetic acid


γ-Aminobutyric acid


Glutamic acid


Aspartic acid


Lactate dehydrogenase


Gasdermin D


NOD-like receptor protein 3


Intercellular cell adhesion molecule-1


Traditional Chinese medicines


Traditional Chinese medicine




Tyrosine kinase receptor b


Glial fibrillary acidic protein





A. annua :

Artemisia annua


Taohong-siwu decoction


Xuefu Zhuyu decoction


Buyang huanwu decoction


Wuling san


Wendan decoction


Dachengqi Decoction


Diamine oxidase


Xiaochengqi Decoction


Tongqiao-huoxue decoction


Focal adhesion kinase




Gastrointestinal failure


Sequential Organ Failure Assessment


Acute Physiology and Chronic Health Evaluation


Multiple Organ Dysfunction Syndrome


D-lactic acid




Intra-abdominal pressure


  1. Jafari AA, Shah M, Mirmoeeni S, Hassani MS, Nazari S, Fielder T, Godoy DA, Seifi A. Paroxysmal sympathetic hyperactivity during traumatic brain injury. Clin Neurol Neurosurg. 2022;212:107081.

    Article  PubMed  Google Scholar 

  2. Injury GBDTB, Spinal Cord Injury C. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):56–87; doi:

  3. Tyler CM, Perrin PB, Klyce DW, Arango-Lasprilla CJ, Dautovich ND, Rybarczyk BD. Predictors of 10-year functional independence trajectories in older adults with traumatic brain injury: a model systems study. NeuroRehabilitation. 2022.

    Article  Google Scholar 

  4. Kalra S, Malik R, Singh G, Bhatia S, Al-Harrasi A, Mohan S, Albratty M, Albarrati A, Tambuwala MM. Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs. Inflammopharmacology. 2022;30(4):1153–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Srisurapanont K, Samakarn Y, Kamklong B, Siratrairat P, Bumiputra A, Jaikwang M, Srisurapanont M. Efficacy and acceptability of blue-wavelength light therapy for post-TBI behavioral symptoms: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(10):e0274025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Khalili H, Ahl R, Paydar S, Sjolin G, Cao Y, Abdolrahimzadeh Fard H, Niakan A, Hanna K, Joseph B, Mohseni S. Beta-blocker therapy in severe traumatic brain injury: a prospective randomized controlled trial. World J Surg. 2020;44(6):1844–53.

    Article  PubMed  Google Scholar 

  7. Najmi A, Javed SA, Al Bratty M, Alhazmi HA. Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents. Molecules. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zhang B, Zhu X, Wang L, Hao S, Xu X, Niu F, He W, Liu B. Dexamethasone impairs neurofunctional recovery in rats following traumatic brain injury by reducing circulating endothelial progenitor cells and angiogenesis. Brain Res. 2019;1725:146469.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang B, Xu X, Niu F, Mao X, Dong J, Yang M, Gao F, Liu B. Corticosterone replacement alleviates hippocampal neuronal apoptosis and spatial memory impairment induced by dexamethasone via promoting brain corticosteroid receptor rebalance after traumatic brain injury. J Neurotrauma. 2020;37(2):262–72.

    Article  PubMed  Google Scholar 

  10. Jeong DU, Bae S, Macks C, Whitaker J, Lynn M, Webb K, Lee JS. Hydrogel-mediated local delivery of dexamethasone reduces neuroinflammation after traumatic brain injury. Biomed Mater. 2021.

    Article  PubMed  Google Scholar 

  11. Macks C, Jeong D, Bae S, Webb K, Lee JS. Dexamethasone-loaded hydrogels improve motor and cognitive functions in a rat mild traumatic brain injury model. Int J Mol Sci. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ahmed Z. Current clinical trials in traumatic brain injury. Brain Sci. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lengel D, Huh JW, Barson JR, Raghupathi R. Progesterone treatment following traumatic brain injury in the 11-day-old rat attenuates cognitive deficits and neuronal hyperexcitability in adolescence. Exp Neurol. 2020;330:113329.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Amirkhosravi L, Khaksari M, Sheibani V, Shahrokhi N, Ebrahimi MN, Amiresmaili S, Salmani N. Improved spatial memory, neurobehavioral outcomes, and neuroprotective effect after progesterone administration in ovariectomized rats with traumatic brain injury: role of RU486 progesterone receptor antagonist. Iran J Basic Med Sci. 2021;24(3):349–59.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kumar MP, Rajput R, Ralta A, Quintans-Júnior LJ, Gutierrez SJ, Barbosa-Filho JM, Shekhawat D, Radotra BD, Gupta SK, Medhi B. Evaluation of progesterone receptor antagonist and maxi-K channel agonist as neuroprotective in feeney’s weight drop model of TBI. Neurol India. 2022;70(4):1601.

    Article  PubMed  Google Scholar 

  16. Farahani F, Khaksari M, Amiresmaili S, Iranpour M, Shahrokhi N, AsadiKaram G, Soltani Z. Possible involvement of female sex steroid hormones in intracellular signal transduction mediated by cytokines following traumatic brain injury. Brain Res Bull. 2022;178:108–19.

    Article  CAS  PubMed  Google Scholar 

  17. Sara S, Mohammad K, Nader S, Maryam I, Marzieh S, Elham J, Neda S. Using the NGF/IL-6 ratio as a reliable criterion to show the beneficial effects of progesterone after experimental diffuse brain injury. Heliyon. 2020;6(4):e03844.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mair O, Greve F, Lefering R, Biberthaler P, Hanschen M, TraumaRegister DGU. The outcome of severely injured patients following traumatic brain injury is affected by gender-A retrospective, multicenter, matched-pair analysis utilizing data of the TraumaRegister DGU((R)). Front Neurosci. 2022;16:974519.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Korley F, Pauls Q, Yeatts SD, Jones CMC, Corbett-Valade E, Silbergleit R, Frankel M, Barsan W, Cahill ND, Bazarian JJ, et al. Progesterone treatment does not decrease serum levels of biomarkers of glial and neuronal cell injury in moderate and severe traumatic brain injury subjects: a secondary analysis of the progesterone for traumatic brain injury, experimental clinical treatment (ProTECT) III trial. J Neurotrauma. 2021;38(14):1953–60.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lopez AJ, ElSaadani M, Jacovides CL, Georges A, Culkin MC, Ahmed S, Kumar MA, Kaplan LJ, Smith DH, Pascual JL. Beta blockade in TBI: dose-dependent reductions in BBB leukocyte mobilization and permeability in vivo. J Trauma Acute Care Surg. 2022;92(5):781–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Singer KE, McGlone ED, Collins SM, Wallen TE, Morris MC, Schuster RM, England LG, Robson MJ, Goodman MD. Propranolol reduces p-tau accumulation and improves behavior outcomes in a polytrauma murine model. J Surg Res. 2023;282:183–90.

    Article  CAS  PubMed  Google Scholar 

  22. Schroeppel TJ, Sharpe JP, Shahan CP, Clement LP, Magnotti LJ, Lee M, Muhlbauer M, Weinberg JA, Tolley EA, Croce MA, et al. Beta-adrenergic blockade for attenuation of catecholamine surge after traumatic brain injury: a randomized pilot trial. Trauma Surg Acute Care Open. 2019;4(1):e000307.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Li O, Guo ZX, Wang C. Effect of acupoint injection of citicoline on serum neuron enolase S100-β protein in rats with traumatic brain injury. J Integr Chin Western Med. 2014; 23 (16) : 1721–2+5.

  24. Yuan XS, Bian XX, Qi CP. Effect of Xuebijing on serum S100B and IL-6 levels after traumatic brain injury in rats. J Jiangsu Univ. 2009;18(01):35–8.

    Article  Google Scholar 

  25. Guo ZX, Li O, Wang C. Effect of acupoint injection of citicoline on neurological dysfunction in rats with traumatic brain injury. China Rehabil. 2013;28(02):90–2.

    Article  Google Scholar 

  26. Puffer RC, Yue JK, Mesley M, Billigen JB, Sharpless J, Fetzick AL, Puccio AM, Diaz-Arrastia R, Okonkwo DO. Recovery trajectories and long-term outcomes in traumatic brain injury: a secondary analysis of the phase 3 citicoline brain injury treatment clinical trial. World Neurosurg. 2019;125:e909–15.

    Article  PubMed  Google Scholar 

  27. Zheng C, Gong J, Zang L, Song D, Ran X, Li J, Jiang B, Xu J, Wu Q. Mechanism of progesterone in treatment of traumatic brain injury based on network pharmacology and molecular docking technology. Med Sci Monit. 2022;28:e937564.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Li ZK, Ma T, Man MH, Tian B. Inhibitory effect and mechanism of Simvastatin on secondary inflammation in mice with traumatic brain injury. Shaanxi Med J. 2022;51(11):1332–6.

    Article  Google Scholar 

  29. Hu Y, Wang X, Ye L, Li C, Chen W, Cheng H. Rosuvastatin alleviates intestinal injury by down-regulating the CD40 pathway in the intestines of rats following traumatic brain injury. Front Neurol. 2020;11:816.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fujimoto T, Morofuji Y, Kovac A, Erickson MA, Deli MA, Niwa M, Banks WA. Pitavastatin ameliorates lipopolysaccharide-induced blood-brain barrier dysfunction. Biomedicines. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Tang JH, Sun XQ, Wang JJ. Inhibitory effect of atorvastatin on neuronal apoptosis in craniocerebral injury rats. Chin J Clin Neurosurg. 2020;25(4):227–30.

    Article  Google Scholar 

  32. Liu S. Atorvastatin inhibits endoplasmic reticulum stress-induced apoptosis and its mechanism by up-regulating Nrf2 expression in brain damaged by hydraulic shock. Hebei Med Univ. 2020.

    Article  Google Scholar 

  33. Lokhandwala A, Hanna K, Gries L, Zeeshan M, Ditillo M, Tang A, Hamidi M, Joseph B. Preinjury statins are associated with improved survival in patients with traumatic brain injury. J Surg Res. 2020;245:367–72.

    Article  CAS  PubMed  Google Scholar 

  34. De Giorgi R, Rizzo Pesci N, Quinton A, De Crescenzo F, Cowen PJ, Harmer CJ. Statins in depression: an evidence-based overview of mechanisms and clinical studies. Front Psychiatry. 2021;12:702617.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Soltani F, Janatmakan F, Jorairahmadi S, Javaherforooshzadeh F, Alizadeh P, Alipour I. Evaluation of the effect of atorvastatin administration on the outcomes of patients with traumatic brain injury: a double-blinded randomized clinical trial. Anesth Pain Med. 2021;11(4):e117140.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mansi IA, English JL, Alvarez CA, Mortensen EM, Pugh MJ. Statins in survivors of traumatic brain injury: a propensity score-matched analysis. Brain Inj. 2020;34(10):1367–74.

    Article  PubMed  Google Scholar 

  37. Denry I, Nedelec JM, Holloway JA. Tranexamic acid-loaded hemostatic nanoclay microsphere frameworks. J Biomed Mater Res B Appl Biomater. 2022;110(2):422–30.

    Article  CAS  PubMed  Google Scholar 

  38. Lech P, Michalik M, Waczynski K, Osowiecka K, Dowgiallo-Gornowicz N. Effectiveness of prophylactic doses of tranexamic acid in reducing hemorrhagic events in sleeve gastrectomy. Langenbecks Arch Surg. 2022;407(7):2733–7.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wallen TE, Singer KE, Baucom MR, England LG, Schuster RM, Pritts TA, Goodman MD. Effects of antifibrinolytics on systemic and cerebral inflammation after traumatic brain injury. J Trauma Acute Care Surg. 2022;93(1):30–7.

    Article  CAS  PubMed  Google Scholar 

  40. Baucom MR, Wallen TE, Singer KE, Youngs J, Schuster RM, Blakeman TC, McGuire JL, Strilka R, Goodman MD. Postinjury treatment to mitigate the effects of aeromedical evacuation after traumatic brain injury in a porcine model. J Surg Res. 2022;279:352–60.

    Article  PubMed  Google Scholar 

  41. Draxler DF, Awad MM, Hanafi G, Daglas M, Ho H, Keragala C, Galle A, Roquilly A, Lyras D, Sashindranath M, et al. Tranexamic acid influences the immune response, but not bacterial clearance in a model of post-traumatic brain injury pneumonia. J Neurotrauma. 2019;36(23):3297–308.

    Article  PubMed  Google Scholar 

  42. Daglas M, Galle A, Draxler DF, Ho H, Liu Z, Sashindranath M, Medcalf RL. Sex-dependent effects of tranexamic acid on blood-brain barrier permeability and the immune response following traumatic brain injury in mice. J Thromb Haemost. 2020;18(10):2658–71.

    Article  CAS  PubMed  Google Scholar 

  43. Nutbeam T, Roberts I, Weekes L, Shakur-Still H, Brenner A, Ageron FX. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data. Br J Anaesth. 2022;129(2):191–9.

    Article  CAS  PubMed  Google Scholar 

  44. Collaborators C-T. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713–23; doi:

  45. Guan XZ, Wang LL, Pan X, Liu L, Sun XL, Zhang XJ, Wang DQ, Yu Y. Clinical indications of recombinant human erythropoietin in a single center: a 10-year retrospective study. Front Pharmacol. 2020;11:1110.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Said MF, Islam AA, Massi MN, Hatta M, Patellongi IJ, Cangara H, Adhimarta W, Nasution RA. Effect of erythropoietin administration on expression of mRNA brain-derived Neutrophic factor, levels of stromal cell-derived Factor-1, and neuron specific enolase in brain injury model Sprague Dawley. Ann Med Surg Lond. 2021;70:102877.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Coimbra-Costa D, Garzon F, Alva N, Pinto TCC, Aguado F, Torrella JR, Carbonell T, Rama R. Intermittent hypobaric hypoxic preconditioning provides neuroprotection by increasing antioxidant activity, erythropoietin expression and preventing apoptosis and astrogliosis in the brain of adult rats exposed to acute severe hypoxia. Int J Mol Sci. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Celorrio M, Rhodes J, Shumilov K, Moritz J, Xiao S, Anabayan I, Sauerbeck A, Kummer T, Friess S. Recombinant human erythropoietin induces neuroprotection, activates MAPK/CREB pathway, and rescues fear memory after traumatic brain injury with delayed hypoxemia in mice. Brain Res. 2022;1795:148074.

    Article  CAS  PubMed  Google Scholar 

  49. Xue Y, Ding J, Liu Y, Pan Y, Zhao P, Ren Z, Xu J, Ye L, Xu Y. Preparation and evaluation of recombinant human erythropoietin loaded tween 80-albumin nanoparticle for traumatic brain injury treatment. Int J Nanomedicine. 2020;15:8495–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu C, Huang C, Xie J, Li H, Hong M, Chen X, Wang J, Wang J, Li Z, Wang J, et al. Potential efficacy of erythropoietin on reducing the risk of mortality in patients with traumatic brain injury: a systematic review and meta-analysis. Biomed Res Int. 2020;2020:7563868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Skrifvars MB, Bailey M, Moore E, Martensson J, French C, Presneill J, Nichol A, Little L, Duranteau J, Huet O, et al. A post hoc analysis of osmotherapy use in the erythropoietin in traumatic brain injury study-associations with acute kidney injury and mortality. Crit Care Med. 2021;49(4):e394–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hellewell SC, Conquest A, Little L, Vallance S, Board J, Bellomo R, Cooper DJ, Morganti-Kossmann MC. EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: a brief report on the Australian EPO-TBI clinical trial. J Clin Neurosci. 2020;76:5–8.

    Article  CAS  PubMed  Google Scholar 

  53. Liu M, Wang AJ, Chen Y, Zhao G, Jiang Z, Wang X, Shi D, Zhang T, Sun B, He H, et al. Efficacy and safety of erythropoietin for traumatic brain injury. BMC Neurol. 2020;20(1):399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Bleimeister IH, Wolff M, Lam TR, Brooks DM, Patel R, Cheng JP, Bondi CO, Kline AE. Environmental enrichment and amantadine confer individual but nonadditive enhancements in motor and spatial learning after controlled cortical impact injury. Brain Res. 2019;1714:227–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Semenenko S, Semenenko A, Khrebtii H, Bodnar R, Semenenko N. The effect of ademol on the DNA fragmentation of cerebral cortex cells in rats with experimental traumatic brain injury. Georgian Med News. 2021;318:143–6 (PMID: 34628396).

    Google Scholar 

  56. Ghalaenovi H, Fattahi A, Koohpayehzadeh J, Khodadost M, Fatahi N, Taheri M, Azimi A, Rohani S, Rahatlou H. The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj. 2018;32(8):1050–5.

    Article  PubMed  Google Scholar 

  57. Hammond FM, Sherer M, Malec JF, Zafonte RD, Dikmen S, Bogner J, Bell KR, Barber J, Temkin N. Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized, controlled trial. J Neurotrauma. 2018;35(19):2298–305.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Shimia M, Iranmehr A, Valizadeh A, Mirzaei F, Namvar M, Rafiei E, Rahimi A, Khadivi A, Aeinfar K. A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury. J Neurosurg Sci. 2021.

    Article  PubMed  Google Scholar 

  59. Lee S, Lee HH, Lee Y, Lee J. Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: a retrospective case-control study. J Rehabil Med. 2020;52(2):jrm00025.

    Article  PubMed  Google Scholar 

  60. Ma HM, Zafonte RD. Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Inj. 2020;34(3):299–315.

    Article  PubMed  Google Scholar 

  61. Chian S, Jiang ZC, Jiang LX, Wang KT, Fan YX, Liao T, Chen WS, Yao WX. Caffeine-induced neurotoxicity mediated by Nrf2 pathway in PC12 cells and zebrafish larvae. J Appl Toxicol. 2022;42(4):629–37.

    Article  CAS  PubMed  Google Scholar 

  62. Lusardi TA, Lytle NK, Gebril HM, Boison D. Effects of preinjury and postinjury exposure to caffeine in a rat model of traumatic brain injury. J Caffeine Adenosine Res. 2020;10(1):12–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Christensen J, Yamakawa GR, Salberg S, Wang M, Kolb B, Mychasiuk R. Caffeine consumption during development alters spine density and recovery from repetitive mild traumatic brain injury in young adult rats. Synapse. 2020;74(4):e22142.

    Article  CAS  PubMed  Google Scholar 

  64. Eyolfson E, Bhatt D, Wang M, Lohman AW, Mychasiuk R. Paternal exposure to exercise and/or caffeine and alcohol modify offspring behavioral and pathophysiological recovery from repetitive mild traumatic brain injury in adolescence. Genes Brain Behav. 2021.

    Article  PubMed  Google Scholar 

  65. Yang S, Li F, Lu S, Ren L, Bian S, Liu M, Zhao D, Wang S, Wang J. Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-kappaB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol. 2022;283:114739.

    Article  CAS  PubMed  Google Scholar 

  66. Kim M, Kim J, Moon S, Choi BY, Kim S, Jeon HS, Suh SW, Kim YM, Choi YK. Korean red ginseng improves astrocytic mitochondrial function by upregulating HO-1-mediated AMPKalpha-PGC-1alpha-ERRalpha circuit after traumatic brain injury. Int J Mol Sci. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Zhai K, Duan H, Wang W, Zhao S, Khan GJ, Wang M, Zhang Y, Thakur K, Fang X, Wu C, et al. Ginsenoside Rg1 ameliorates blood-brain barrier disruption and traumatic brain injury via attenuating macrophages derived exosomes miR-21 release. Acta Pharm Sin B. 2021;11(11):3493–507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Chen W, Guo Y, Yang W, Zheng P, Zeng J, Tong W. Involvement of connexin40 in the protective effects of ginsenoside Rb1 against traumatic brain injury. Cell Mol Neurobiol. 2016;36(7):1057–65.

    Article  CAS  PubMed  Google Scholar 

  69. Salem M, Shaheen M, Tabbara A, Borjac J. Saffron extract and crocin exert anti-inflammatory and anti-oxidative effects in a repetitive mild traumatic brain injury mouse model. Sci Rep. 2022;12(1):5004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Shi Y, Zhou X, Yang R, Ying S, Wang L. Panax notoginseng protects the rat brain function from traumatic brain injury by inhibiting autophagy via mammalian targeting of rapamycin. Aging (Albany NY). 2021;13(8):11207–17.

    Article  CAS  PubMed  Google Scholar 

  71. Jiang T, Zhou X, Jiang H, Ying R, Zhang Z, Cai D, Wu Y, Fang H, Wang L. Efficacy of Sanqi (Radix Notoginseng) in treating cerebral hemorrhage in rats with traumatic brain injury. J Tradit Chin Med. 2021;41(2):262–9.

    Article  PubMed  Google Scholar 

  72. Lin C, Chen C. Protective effect of panax notoginseng total saponins on neuronal apoptosis in rats with traumatic brain injury. Chin General Med. 2021;19(6):932–5.

    Article  Google Scholar 

  73. Luo Y, Chen P, Yang L, Duan X. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Gastrodia elata Blume in the treatment of ischemic stroke. Exp Ther Med. 2022;24(6):742.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Ng CF, Ko CH, Koon CM, Chin WC, Kwong HC, Lo AW, Wong HL, Fung KP, Lau CB, Lam PK, et al. The aqueous extract of rhizome of Gastrodia elata Blume attenuates locomotor defect and inflammation after traumatic brain injury in rats. J Ethnopharmacol. 2016;185:87–95.

    Article  PubMed  Google Scholar 

  75. Yang F, Li G, Lin B, Zhang K. Gastrodin suppresses pyroptosis and exerts neuroprotective effect in traumatic brain injury model by inhibiting NLRP3 inflammasome signaling pathway. J Integr Neurosci. 2022;21(2):72.

    Article  PubMed  Google Scholar 

  76. Wang L, Liu Q, Xiao YA, Zhao KL, Wang JQ, Li JP, Li YY, Yang R. Determination of gastrodin content and its uniformity in Gastrodin tablets by HPLC. Pharm Res. 2022;41(4):230–2.

    Article  CAS  Google Scholar 

  77. Yang Z, Fan R, Sun P, Cui H, Peng W, Luo J, Zhang C, Xiong X, Huang W, Liu W. Rhubarb attenuates cerebral edema via inhibition of the extracellular signal-regulated kinase pathway following traumatic brain injury in rats. Pharmacogn Mag. 2018;14(53):134–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Guo Y, Li Q, Yu X, Liang Y. Rhubarb anthraquinone glycosides protect against cerebral ischemia-reperfusion injury in rats by regulating brain-gut neurotransmitters. Biomed Chromatogr. 2021;35(5):e5058.

    Article  CAS  PubMed  Google Scholar 

  79. Bi F, Ma H, Ji C, Chang C, Liu W, Xie K. Rhein protects against neurological deficits after traumatic brain injury in mice via inhibiting neuronal pyroptosis. Front Pharmacol. 2020;11:564367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Guo K, Yao XY, Wu WJ, Wang BQ, Li ZZ, Ma ZL. The effect of emodin on acute severe craniocerebral injury in rats was studied based on NF-κB/Nrf2 pathway. J Tradit Chin Med. 2021;36(7):1519–24.

    Article  CAS  Google Scholar 

  81. Kang L. Effects of Ginkgo Biloba Extract (EGb761) on traumatic cerebral edema in rats and its potential mechanism. Shenyang Med Coll. 2019. doi: CNKI:SUN:ZLXZ.0.2019-13-056

  82. Chen FH, Wang Y, Fang JY, Wu ZS, Chen ZX, Xie Y, Xiao C, Zhao X. Effect of ginkgolide B on Omi/HtrA2 signaling pathway of apoptosis of nerve cells after external injury. J Med Res. 2019;48(01):83–8.

    Article  CAS  Google Scholar 

  83. Zhao XY, Yu D, Shi X, Hou S, Teng D. Resveratrol reduces p38 mitogen-activated protein kinase phosphorylation by activating Sirtuin 1 to alleviate cognitive dysfunction after traumatic brain injury in mice. NeuroReport. 2022;33(11):463–9.

    Article  CAS  PubMed  Google Scholar 

  84. Yu D, Zhao XY, Meng QP, Teng D, Deng K, Lin N. Resveratrol activates the SIRT1/PGC-1 pathway in mice to improve synaptic-related cognitive impairment after TBI. Brain Res. 2022;1796:148109.

    Article  CAS  PubMed  Google Scholar 

  85. Feng Y, Ju Y, Yan Z, Ji M, Li J, Wu Q, Yang M, Sun G. Resveratrol attenuates autophagy and inflammation after traumatic brain injury by activation of PI3K/Akt/mTOR pathway in rats. Folia Neuropathol. 2022;60(2):153–64.

    Article  PubMed  Google Scholar 

  86. Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Curcumin and curcuma longa extract in the treatment of 10 types of autoimmune diseases: a systematic review and meta-analysis of 31 randomized controlled Trials. Front Immunol. 2022;13:896476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Attari F, Ghadiri T, Hashemi M. Combination of curcumin with autologous transplantation of adult neural stem/progenitor cells leads to more efficient repair of damaged cerebral tissue of rat. Exp Physiol. 2020;105(9):1610–22.

    Article  CAS  PubMed  Google Scholar 

  88. Qian F, Han Y, Han Z, Zhang D, Zhang L, Zhao G, Li S, Jin G, Yu R, Liu H. In situ implantable, post-trauma microenvironment-responsive, ROS depletion hydrogels for the treatment of traumatic brain injury. Biomaterials. 2021;270:120675.

    Article  CAS  PubMed  Google Scholar 

  89. Li G, Duan L, Yang F, Yang L, Deng Y, Yu Y, Xu Y, Zhang Y. Curcumin suppress inflammatory response in traumatic brain injury via p38/MAPK signaling pathway. Phytother Res. 2022;36(3):1326–37.

    Article  CAS  PubMed  Google Scholar 

  90. Sun G, Miao Z, Ye Y, Zhao P, Fan L, Bao Z, Tu Y, Li C, Chao H, Xu X, et al. Curcumin alleviates neuroinflammation, enhances hippocampal neurogenesis, and improves spatial memory after traumatic brain injury. Brain Res Bull. 2020;162:84–93.

    Article  CAS  PubMed  Google Scholar 

  91. Dong MH, Xiao YC. Therapeutic effect of salvia miltiorrhizae injection combined with cerebral circulation therapy instrument on convalescent patients with cerebral infarction. Chin Community Physicians. 2021;37(14):29–30.

    Article  Google Scholar 

  92. Hu D, Chen WH. Effects of Danshen Injection combined with bunchcare on lung function and serum levels of procalcitonin high mobility group protein B1 hemophilia factor in patients with type I respiratory failure. Chin Med Clin. 2021;21(8):1401–3.

    Article  Google Scholar 

  93. Feng XL. Clinical effect of Salvia miltiorrhiza injection combined with ulicrine in the treatment of acute cerebral infarction and the effect on hemorheology of patients. Clin Med Eng. 2021;28(4):503–4.

    Article  Google Scholar 

  94. Wang J, Xu C, Zhang K, Shi J, Liu Z, Wang X, Guo M, Lv J, Ding X. Inhibition of ASC enhances the protective role of salvianolic acid A in traumatic brain injury via inhibition of inflammation and recovery of mitochondrial function. Folia Neuropathol. 2021;59(1):50–66.

    Article  PubMed  Google Scholar 

  95. Huang Y, Long X, Tang J, Li X, Zhang X, Luo C, Zhou Y, Zhang P. The attenuation of traumatic brain injury via inhibition of oxidative stress and apoptosis by tanshinone IIA. Oxid Med Cell Longev. 2020;2020:4170156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Gugliandolo E, D’Amico R, Cordaro M, Fusco R, Siracusa R, Crupi R, Impellizzeri D, Cuzzocrea S, Di Paola R. Neuroprotective effect of Artesunate in experimental model of traumatic brain injury. Front Neurol. 2018;9:590.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Zhou Z, Hou J, Li Q. Artesunate attenuates traumatic brain injury-induced impairments in rats. Transl Neurosci. 2020;11(1):309–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Huang W, Wang Y, Wu J. Effect of Salvia miltiorrhiza injection on neurons in rats with brain injury and its relationship with Persephin expression. Eval Anal Hosp Drugs China. 2019; 19 (12) : 1448–50 + 54; doi:

  99. Wang WZ, Pan YZ, Wei JB, Huang LP, Huang X, Li K. The effects of Rhizoma drynariae on interleukin-2 and T-lymphocyte levels in rats after severe head injury. J Ethnopharmacol. 2012;142(1):300–4.

    Article  PubMed  Google Scholar 

  100. Wang W, Li H, Yu J, Hong M, Zhou J, Zhu L, Wang Y, Luo M, Xia Z, Yang ZJ, et al. Protective effects of Chinese herbal medicine Rhizoma drynariae in rats after traumatic brain injury and identification of active compound. Mol Neurobiol. 2016;53(7):4809–20.

    Article  CAS  PubMed  Google Scholar 

  101. Pan L, Peng C, Wang L, Li L, Huang S, Fei C, Wang N, Chu F, Peng D, Duan X. Network pharmacology and experimental validation-based approach to understand the effect and mechanism of Taohong Siwu Decoction against ischemic stroke. J Ethnopharmacol. 2022;294:115339.

    Article  CAS  PubMed  Google Scholar 

  102. Wang J, Wei C, Pan M, Liu X, Pan Y. Effect of Huoxue Huayu decoction on Wnt/beta-catenin signal pathway expression in rats with severe traumatic brain injury. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(9):1101–6.

    Article  PubMed  Google Scholar 

  103. Wang XR, Song DD, Tao TQ, He T, Wu XD, Li XM, Liu XH. Qi-regulating and blood circulation-promoting therapy improves health status of stable angina pectoris patients with depressive symptoms. Evid Based Complement Altern Med. 2021;2021:7319417.

    Article  Google Scholar 

  104. Yang ZY, Tang T, Li PF, Li XX, Wu Y, Feng DD, Hu MR, Dai F, Zheng F, Zhang W, et al. Systematic analysis of tRNA-derived small RNAs reveals therapeutic targets of Xuefu Zhuyu decoction in the cortexes of experimental traumatic brain injury. Phytomedicine. 2022;102:154168.

    Article  CAS  PubMed  Google Scholar 

  105. Li T, Hu E, Li P, Yang Z, Wu Y, Ding R, Zhu X, Tang T, Wang Y. Metabolomics deciphers potential targets of Xuefu Zhuyu decoction against traumatic brain injury in rat. Front Pharmacol. 2020;11:559618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Wu SY, Wen KY, Chou HC, Chiu SM, Hou YC, Chang YY. Early intervention combining Chinese and Western medicine in traumatic brain injury with diffuse axonal injury: a report of three cases. J Tradit Complement Med. 2020;10(5):504–10.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Wei CZ. Intervention effect and application risk of different Huoxue Huayu prescriptions on nerve regeneration and repair in acute stage of severe craniocerebral injury in rats. Guangxi Med Univ. 2020.

    Article  Google Scholar 

  108. Sun CC, Liu T, Chen JJ. Effects of Wuling Powder on brain edema and mitochondrial biosynthesis in craniocerebral trauma rats. Chin J Prevent Med. 2018;36(02):194–7.

    Article  Google Scholar 

  109. Fang J, Zhang XW, Zhang J. Effects of supplemented Wuling Powder on serum inflammatory factors in patients with moderate cerebral edema after traumatic brain injury. Chin Mod Doctor. 2019;57(31):111–5.

    Google Scholar 

  110. Wang Q, Chen J, Zhang Y, Xu D, Wu H, Lin P, He L, Qin Z, Yao Z. Metabolic profile and potential mechanisms of Wendan decoction on coronary heart disease by ultra-high-performance quadrupole time of flight-mass spectrometry combined with network pharmacology analysis. J Sep Sci. 2023;46(1):e2200456.

    Article  CAS  PubMed  Google Scholar 

  111. Huang CC, Chiang PY, Cheng YC, Huang BR. Efficacy and safety of wendan decoction for acute brain injury: a randomized controlled study. J Altern Complement Med. 2020;26(5):392–7.

    Article  PubMed  Google Scholar 

  112. Fu SL, Zhu LN, Yin HH, Jiang Y, Zhu JC. Da-Cheng-Qi decoction combined with lactobacillus acidophilus improves gastrointestinal function of traumatic brain-injured model mice. Chin J Integr Med. 2020;26(10):762–8.

    Article  CAS  PubMed  Google Scholar 

  113. Peng L, Wang J, Pan Y, Du Y, Huang G. Effects of Xiao-Cheng-Qi decoction on brain edema and inflammatory factors in rats with severe traumatic brain injury. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021;33(11):1347–52.

    Article  PubMed  Google Scholar 

  114. Peng LL, Liang RJ, Ning L, Du YH, Huang GH. Effect of Xiaochengqi Decoction on intestinal flora in acute stage of severe craniocerebral injury model rats. Chin Med J. 2022;63(12):1170–8.

    Article  Google Scholar 

  115. Zhou X, Shao T, Xie X, Ding M, Jiang X, Su P, Jin Z. Tongqiao huoxue decoction for the treatment of acute ischemic stroke: a systematic review and meta-analysis. J Ethnopharmacol. 2022;283:114693.

    Article  CAS  PubMed  Google Scholar 

  116. Wu SP, Wang N, Zhao L. Network pharmacology reveals the mechanism of activity of tongqiao huoxue decoction extract against middle cerebral artery occlusion-induced cerebral ischemia-reperfusion injury. Front Pharmacol. 2020;11:572624.

    Article  CAS  PubMed  Google Scholar 

  117. Huang Z, Chen Y, Xiao Q, Kuang W, Liu K, Jiang Y, Wen X, Qin W, Liu Y, Liu T. Effect of acupuncture for disorders of consciousness in patients with stroke: a systematic review and meta-analysis. Front Neurol. 2022;13:930546.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Hung SY, Chung HY, Luo ST, Chu YT, Chen YH, MacDonald IJ, Chien SY, Kotha P, Yang LY, Hwang LL, et al. Electroacupuncture improves TBI dysfunction by targeting HDAC overexpression and BDNF-associated Akt/GSK-3beta signaling. Front Cell Neurosci. 2022;16:880267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Liu T, Lu Y, Yu J, Kuang W, Wang X, Jiang Y, Qiu X, Wen X, Zeng Y, Zhang G, et al. Effect of auricular electroacupuncture combined with body acupuncture in improving the consciousness of patients after traumatic brain injury: Study protocol for a randomized controlled trial. Medicine (Baltimore). 2019;98(30):e16587.

    Article  PubMed  Google Scholar 

  120. Xing X, Jiang RL, Lei S, Zhi YH, Zhu MF, Huang LQ, Hu MH, Lu J, Fang K, Wang QY. Electroacupuncture in treatment of acute gastrointestinal injury in patients with severe traumatic brain injury: a multicenter randomized controlled trial. Chin J Integr Med. 2022.

    Article  PubMed  Google Scholar 

  121. Zhang F, Wu R, Liu Y, Dai S, Xue X, Li Y, Gong X. Nephroprotective and nephrotoxic effects of Rhubarb and their molecular mechanisms. Biomed Pharmacother. 2023;160:114297.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors thank the China National Natural Fund Committee for their support.


Funding for this work was supported by the National Natural Fund of China (No. 81904023).

Author information

Authors and Affiliations



WW and YW conceptualized the manuscript; CW conducted the literature search; CW, JW, JY and QT wrote and revised the manuscript; XL, YZ, DC, YZ, YM drafted the figures and tables with inputs from WW and YW; WW approved the final version of the paper. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yanjun Wang or Wenzhu Wang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, C., Wang, J., Yu, J. et al. Therapy of traumatic brain injury by modern agents and traditional Chinese medicine. Chin Med 18, 25 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Traumatic brain injury
  • Pharmacological therapies
  • Traditional Chinese medicine
  • Modern agents